ArticleBMC cancer2014
The effect of patient characteristics on second primary cancer risk in France.
Article in BMC cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 9 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- SEOM-TTCC clinical guideline for nasopharyngeal carcinoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Risks of colorectal and extracolonic cancers following colorectal cancer: a systematic review and meta-analysis.JNCI cancer spectrum · 2025Pooled it
- Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.Breast cancer research : BCR · 2023Pooled it
- Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Pooled it
- SEOM-TTCC clinical guideline in nasopharynx cancer (2021).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Guideline
- Risk of second primary cancer among breast cancer patients: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.British journal of cancer · 2019Pooled it
- Temporal trends in the risk of developing multiple primary cancers: a systematic review.BMC cancer · 2016Pooled it
- Risk and Survival Outcomes of Secondary Primary Malignancies in Chinese Lymphoma Patients in the Era of Modern Targeted Therapies: A Single-Center Retrospective Cohort Study.Blood and lymphatic cancer : targets and therapy · 2026Article
- Role of muscle glucometabolism derived fromQuantitative imaging in medicine and surgery · 2025Article
- Socio-economic inequalities in second primary cancer incidence: A competing risks analysis of women with breast cancer in England between 2000 and 2018.International journal of cancer · 2025Article
- Incidence, Risk and Trends of Multiple Primary Cancers in Patients With Colorectal Cancer: Evidence From the South Australian Cancer Registry.Cancer medicine · 2025Article
- Prevalence of Constitutional Pathogenic Variant in a Cohort of 348 Patients With Multiple Primary Cancer Addressed in Oncogenetic Consultation.Molecular genetics & genomic medicine · 2025Article
- Risk of second primary cancers in nodal non-Hodgkin lymphoma patients by primary lymph node location: a retrospective cohort population-based study.Annals of medicine and surgery (2012) · 2024Article
- Relative risk of second malignant neoplasms highest among young adult cancer patients - a population-based registry study in Finland.Acta oncologica (Stockholm, Sweden) · 2024Article
- An Integrated Cancer Prevention Strategy: the Viewpoint of the Leon Berard Comprehensive Cancer Center Lyon, France.Cancer prevention research (Philadelphia, Pa.) · 2024Article
- The epidemiology of multiple primary cancers in Belgium (2004-2017): Incidence, proportion, risk, stage and impact on relative survival estimates.BMC cancer · 2023Article
- Article
- Evolution of the Incidence of Oral Cavity Cancers in the Elderly from 1990 to 2018.Journal of clinical medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough cancer survivors are known to be at greater risk of developing second primary cancer (SPC), SPC incidence estimates in France are thus far lacking. We used a multivariate approach to compute these estimates and analyzed the effect of patient characteristics (gender, age at diagnosis, first cancer site, year of diagnosis and follow-up) on SPC risk.
methodsData from ten French population-based cancer registries were used to establish a cohort of all patients diagnosed with a first cancer between 1989 and 2004 and followed up until December 31, 2007. The person-year approach was used to estimate standardized incidence ratios (SIRs) and excess absolute risks (EARs) of metachronous SPC. Multivariate Poisson regression models were then used to model SIRs and EARs separately by gender, adjusting for age, year of diagnosis, follow-up and first cancer site.
resultsAmong the 289,967 followed-up patients with a first primary cancer, 21,226 developed a SPC. The SIR was of 1.36 (95% CI, 1.35-1.38) and the EAR was of 39.4 excess cancers per 10,000 person-years (95% CI, 37.4-41.3). Among male and female patients, multivariate analyses showed that age, year of diagnosis, follow-up and first cancer site were often independently associated with SIRs and EARs. Moreover, the EAR of SPC remained elevated during patient follow-up.
conclusionsFrench cancer survivors face a dramatically increased risk of SPC which is probably related to the high rate of tobacco and alcohol consumption in France. Multivariate modeling of SPC risk will facilitate the construction of a tailored prediction tool to optimize SPC prevention and early detection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.